Cassava Sciences simufilam Phase 3 trial fails all endpoints; Alzheimer's program discontinued

FILANA THERAPEUTICS, INC.

Phase 3 REFOCUS-ALZ failed all co-primary, secondary, and biomarker endpoints.
Simufilam showed no significant difference vs placebo on ADAS-COG12 or ADCS-ADL; p-values 0.37-0.67 and 0.16-0.23.
Cassava will discontinue all simufilam Alzheimer's development by Q2 2025.
Company had $128.6M cash at Dec 31, 2024; exploring TSC-related epilepsy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.